SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Schein Pharmaceutical Inc – ‘8-K’ for 11/6/98

As of:  Tuesday, 11/17/98   ·   For:  11/6/98   ·   Accession #:  922423-98-1312   ·   File #:  1-14019

Previous ‘8-K’:  ‘8-K’ on 10/27/98 for 10/16/98   ·   Next:  ‘8-K’ on 5/4/00 for 5/3/00   ·   Latest:  ‘8-K’ on 7/19/00 for 7/6/00

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

11/17/98  Schein Pharmaceutical Inc         8-K:5,7    11/06/98    2:28K                                    Kramer Levin Naf… LLP/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report on Form 8-K                             4      9K 
 2: EX-99.1     Amended and Restated Credit Agreement                 12     50K 


8-K   —   Current Report on Form 8-K
Document Table of Contents

Page (sequential) | (alphabetic) Top
 
11st Page   -   Filing Submission
2Item 5. Other Events
"Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
8-K1st Page of 4TOCTopPreviousNextBottomJust 1st
 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant To Section 13 Or 15(D) of the Securities Exchange Act Of 1934 Date of Report: November 6, 1998 SCHEIN PHARMACEUTICAL, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 1-14019 11-2726505 ----------------------------------- -------------------------------------- (Commission File Number) (I.R.S. EmployerIdentification No.) 100 Campus Drive Florham Park, NJ 07932 (Address of principal executive offices) 973-593-5500 ------------------------------------------------------ (Registrant's telephone number, including area code)
8-K2nd Page of 4TOC1stPreviousNextBottomJust 2nd
ITEM 5. OTHER EVENTS. Schein Pharmaceutical, Inc. the ("Company") has entered into an Amended and Restated Credit Agreement with its bank group dated November 6, 1998. The amendment provides for an increase in permissible investments and certain indebtedness. Additionally, it modified the minimum net worth requirement and adjusted certain required ratios (as defined therein) including leverage, fixed charge coverage and interest expense coverage. The amendment increases the future interest rate spread the Company will pay under the revolving credit and term loan agreements depending upon the Company's performance against leverage and interest expense ratios. A copy of the Amended and Restated Credit Agreement, referred to above is attached to this Form 8-K as Exhibit and is incorporated herein by reference. ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS. (C) EXHIBITS 99.1 Amended and Restated Credit Agreement Dated November 6, 1998
8-K3rd Page of 4TOC1stPreviousNextBottomJust 3rd
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SCHEIN PHARMACEUTICAL, INC Dated: November 17, 1998 By: -------------------------------- Dariush Ashrafi Executive Vice President and Chief Financial Officer
8-KLast Page of 4TOC1stPreviousNextBottomJust 4th
INDEX TO EXHIBIT Exhibit No. Description ----------- ----------- 99.1 Amended and Restated Credit Agreement Dated November 6, 1998

Dates Referenced Herein   and   Documents Incorporated by Reference

Referenced-On Page
This ‘8-K’ Filing    Date First  Last      Other Filings
Filed on:11/17/983None on these Dates
For Period End:11/6/9814
 List all Filings 
Top
Filing Submission 0000922423-98-001312   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Apr. 25, 3:20:50.1pm ET